Liver stiffness test may help transplant patients ditch dangerous drugs
NCT ID NCT07206277
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times
Summary
After a liver transplant, patients must take lifelong anti-rejection drugs that can cause kidney problems, diabetes, heart disease, and cancer. This study tests whether a simple ultrasound-like test called a fibroscan can identify patients who can safely reduce their anti-rejection medication by 30% without risking organ rejection. The study will enroll 50 adults who are at least 2 years post-transplant and have no recent rejection or autoimmune liver disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G2R3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.